NCT00141050.

Study name	Public title: Safety and efficacy study of dexmethylphenidate in children with ADHD Scientific title: as above
Methods	Randomised controlled double‐blind, cross‐over trial Study duration: not reported
Participants	Sample size (actual): 90 Inclusion criteria DSM‐IV diagnosis of ADHD Male and female participants aged 6‐12 years Exclusion criteria Inability to understand or follow instructions Is pregnant Diagnosis of tic disorder
Interventions	d‐MPH (2 unspecified doses) MPH (2 unspecified doses) Placebo
Outcomes	ADHD symptoms Reduction of symptoms in attention and deportment assessed at 0.5, 1, 2, 3, 4, 6, 8, 10, 11, and 12 h post‐dose Total number of serious AEs Safety and tolerability. Scale/measurement methods and timing of outcome assessment not reported General behaviour Parent's assessment of patient behaviour across all treatment periods as measured by change from baseline Non‐serious AEs Safety and tolerability. Scale/measurement methods and timing of outcome assessment not reported
Starting date	May 2005 (registration date). Starting date not reported
Contact information	Name: Matthew Brams, MD (Principal Investigator) Affiliation: Bayou City Research
Notes	Sponsor: Novartis Pharmaceuticals Declaration of interest: not reported